Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 25, 2022 9:37am
$1.50 Avg price target
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Antibe Therapeutics (ATBPF – Research Report), with a price target of C$2.00. The
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 25, 2022 9:33am
Price Target $2 us
Antibe Therapeutics (ATBPF) In a report released today, Stefan Quenneville from Echelon Wealth Partners maintained a Buy rating on Antibe Therapeutics, with a price target of
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 24, 2022 6:57pm
RE:RE:RE:Question on interview
Hahaha - wouldn't rely on prayer here. Focus on a deep understanding and an ability to pivot where/when needed. This is where the cash comes in useful ... to solve problems. I'm going to
...more
(2)
•••
Doccole
X
View Profile
View Bullboard History
Comment by
Doccole
on Nov 24, 2022 6:18pm
RE:RE:Question on interview
I look forward to being back in the trials. Nice to see the zacks report. Nice to see some inside buying. More positive than usual. let's pray this drug change is the one
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 24, 2022 5:10pm
RE:Question on interview
First - the acute trial is only 5 days (as per Dan). 2nd - dosing will be 2-4 fold less than we had. Liver enzyme is not an issue for acute. Also - 5 days is self-limiting and after 5 days, it's
...more
(37)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Nov 24, 2022 4:01pm
Video Recap - $ATE CEO Dan Legault & Radius Research
Webinar Recap: Antibe Therapeutics $ATE w CEO Dan Legault - Pitch, Deep Dive and Q&A - https://youtu.be/5_M2ucaYGoQ CEO Dan Legault provides a corporate update, including the
...more
(33)
•••
Inthepez
X
View Profile
View Bullboard History
Comment by
Inthepez
on Nov 24, 2022 1:49pm
RE:RE:RE:RE:RE: Question on interview
Probably another response to dumpster or his other accounts. Don't bother man. He just spreads fud for day flipping. He sucks at it too; which makes the fud entertaining and was the only redeeming
...more
(43)
•••
guilelesscat
X
View Profile
View Bullboard History
Comment by
guilelesscat
on Nov 24, 2022 11:38am
RE:RE:RE:RE: Question on interview
Because you'd be selling at a massive loss? Ya know... the main reason ppl don't sell investments. I'd rather take my chances at this point. What a stupid question.
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Nov 24, 2022 11:24am
RE:RE:RE: Question on interview
Mugoo hasn't reposnded in 2 hours either a huge post coming or ask many pumpy questions about why you should stay invested. Ibd? Accumulation? Cash in the bank? Same old poop comin soon
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 24, 2022 10:43am
RE:RE: Question on interview
Initiated animal de-risking studies for new formulation; saved resources by bypassing previously planned molar extraction clinical study (no timeline given for test results.)
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Nov 24, 2022 10:21am
RE:Question on interview
And in October these tests are not done. "We can" not "we have" we can capture the necessary data via a set of lower cost, de-risking animal studies
(2)
•••
Doccole
X
View Profile
View Bullboard History
Post by
Doccole
on Nov 24, 2022 8:36am
Question on interview
Dan reported that Antibe never saw the elevated liver enzymes in the animal studies and it wasn't until after it was discovered. how does this new formation and new tests in animal studies rule
...more
(450)
•••
davgro
X
View Profile
View Bullboard History
Post by
davgro
on Nov 23, 2022 11:05pm
Zacks Small-Cap Research Report - ATBPF - 22Nov22
Here is a link to a PDF copy of the most recent Zacks Small-Cap Research Report for ATBPF released on November 22, 2022. Conclusion: "The new formulation for otenaproxesul is an
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 23, 2022 4:39pm
RE:Webinar - 10,000 foot level notes
Thanks Harper - just a couple things to add ... Liver issue derisked - manufacture is now the top concern if there is one (or something like that). Least risky point ever - but there's always
...more
(55)
•••
Harper75
X
View Profile
View Bullboard History
Post by
Harper75
on Nov 23, 2022 4:32pm
Webinar - 10,000 foot level notes
I had a couple of take-aways from the webinar. Some previously mentioned on this board - apologies for duplicates (or if I misheard Dan). I personally find this preso difficult to listen
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >